- Price is above the Trend Line, keeping the weekly tape constructive.
- Activity pressure is positive on the latest completed week.
B8FK
GER
Week ended 07 Aug 2026
Weekly Investor Report
Biofrontera AG · Healthcare · Drug Manufacturers - Specialty & Generic
Latest close
2.60 EUR
3.2%
latest week
Weekly setup
Mixed setup
The weekly trend is not active. Price is 3.7% above the Trend Line and sits at 51.4% of its 52-week range. The latest completed week returned 3.2%, after a 7.9% four-week move. The latest factor snapshot indicates quality is middle-of-the-pack; growth is moderate; valuation is neither clearly cheap nor expensive. The latest news-sentiment score is 50/100. Near-term considerations: volume confirmation is below normal.
Setup score
41
out of 100
Latest Close
2.60 EUR
7 Aug 2026
1W Return
3.2%
latest completed week
4W Return
7.9%
short-term follow-through
12W Return
10.2%
quarterly tape
Trend Breadth
36.5%
19 of 52 weeks active
Volume Ratio
0.5x
vs 13-week average
- The trend backdrop is inactive, so price action has not confirmed a constructive regime.
- Price is below Fair Value, so the market is still discounting the latest tape.
- Next-week expectancy is negative at 38.55% based on similar historical setup states.
- Activity pressure is weak, so confirmation is not yet broad enough.
- Trend Line remains the key weekly regime level.
- Activity pressure is the gauge to monitor for confirmation or fade.
- A volume ratio above 1.5x would show stronger participation in the next move.
Price follow-through
3.2%
Latest completed week; four-week move 7.9%.
Indicator stack
20/65
Trend and activity pressure are weighted against the latest 12-week confirmation window.
Trend backdrop
Active
The trend backdrop defines the current weekly regime.
Patient Capital
Quiet
Activity-pressure buy-signal status for institutional accumulation timing.
Next-Week Expectancy
Negative 38.55%
Historical one-week expectancy contributes to the evidence score when direction is confirmed.
News sentiment
50/100
4 relevant articles in the latest sentiment read.
01 · Price action
Study the full chart
Where price is—and whether the trend supports it
The weekly trend is not active. Price is 3.7% above the Trend Line and sits at 51.4% of its 52-week range. The latest completed week returned 3.2%, after a 7.9% four-week move.
52-week price path
Price vs Trend Line and Fair Value
Price
Trend Line
Fair Value
02 · Volume and demand
Is real participation confirming the move?
Latest weekly volume is 0.5x the 13-week average. Participation is below its recent norm, so price strength is not receiving full volume confirmation.
26-week volume confirmation
Bar height shows volume; colour shows the weekly price direction
13 Feb
20 Feb
27 Feb
6 Mar
13 Mar
20 Mar
27 Mar
3 Apr
10 Apr
17 Apr
24 Apr
1 May
8 May
15 May
22 May
29 May
5 Jun
12 Jun
19 Jun
26 Jun
3 Jul
10 Jul
17 Jul
24 Jul
31 Jul
7 Aug
Up week
Down week
Demand beneath price
Activity pressure and institutional-style signals
These indicators assess whether participation is improving beneath the headline price move. They are supporting evidence, not proof of institutional buying.
Activity pressure path
Latest 0.2012-week average 0.10
12-week confirmation
Trend active0/12Active trend-backdrop weeks in the latest 12-week window.
Positive pressure1/12Weeks with constructive activity pressure in the latest 12-week window.
Positive leadership0/12Weeks with positive relative leadership in the latest 12-week window.
Activity pressure0.20Current proprietary activity-pressure read.
Buy signals0Accumulation signal count in the latest 12 weeks.
Reversal markers0No reversal markers
No recent accumulation markers. No reversal markers.
03 · Momentum and leadership
Is performance persistent—and is the stock leading?
Performance is 7.9% over four weeks, 10.2% over 12 weeks, and -4.1% over one year. The current trend has remained active for 0 consecutive weeks.
Performance by holding period
Active trend streak0 weeks
Active weeks in one year19
Trend breadth36.5%
Activity pressure vs relative leadership
Activity pressureRelative leadership
Pressure0.28Latest activity-pressure read.
Pressure change125.3%Four-week change in activity pressure.
Leadership-6.51Latest relative-leadership reading.
RS change32.9%Four-week change in relative leadership.
04 · Fundamentals and valuation
Open full factor analysis
What investors are paying for—and the quality behind it
The latest factor snapshot indicates quality is middle-of-the-pack; growth is moderate; valuation is neither clearly cheap nor expensive.
Factor week 09 Aug 2026
Financial statements through 31 Mar 2026
Field coverage 79%
Model confidence 74%
Relative factor standing
Higher display scores are better. Each score is converted from the underlying universe rank, where rank 1 is best.
Overall factor strength63/100Blend of value, momentum, and quality. Underlying universe rank 38; rank 1 is best.
Value54/100Relative valuation strength. Underlying universe rank 47; rank 1 is best.
Quality53/100Profitability and accounting quality. Underlying universe rank 48; rank 1 is best.
Momentum55/100Medium-term price momentum. Underlying universe rank 46; rank 1 is best.
Growth54/100Revenue and earnings growth. Underlying universe rank 47; rank 1 is best.
Quality and valuation are separate questions
A strong company can still carry a demanding valuation. This report shows profitability, growth, balance-sheet strength, and the price paid for those characteristics separately.
Valuation
How much investors are paying for earnings, sales, and cash flow.
- P/E
- 6.1x Price divided by trailing earnings.
- Price / sales
- 1.4x Market value relative to trailing revenue.
- EV / EBITDA
- - Enterprise value relative to operating cash earnings.
- Free-cash-flow yield
- -39.3% Free cash flow as a share of enterprise value.
Business quality
Margins and the return generated on invested capital.
- Gross margin
- 88.7% Gross profit retained from each unit of revenue.
- Operating margin
- -20.7% Operating profit retained from revenue.
- Free-cash-flow margin
- -39.0% Free cash flow generated from revenue.
- Return on invested capital
- -14.1% Operating return generated on invested capital.
Growth and financial strength
Recent business growth and accounting strength.
- Revenue growth
- 8.3% Latest one-year revenue growth.
- EPS growth
- - Latest one-year earnings-per-share growth.
- Free-cash-flow growth
- - Latest one-year free-cash-flow growth.
- Piotroski F-score
- 3/9 Nine-point accounting-strength checklist.
Shareholder return and balance sheet
Cash returned to owners and financial leverage.
- Dividend yield
- - Cash dividends relative to market value.
- Buyback yield
- 0.0% Net share repurchases relative to market value.
- Shareholder yield
- 0.0% Dividend yield plus net buyback yield.
- Net debt / EBITDA
- 1.6x Balance-sheet debt relative to operating cash earnings.
05 · Ownership, options, and sentiment
What other market participants are doing
Options, insider transactions, market sentiment, and activity-pressure signals can confirm or challenge the price story. None should be used alone.
Insider activity-
No recent insider transactions are stored for this company.
News sentiment50/100
Weighted news tone is neutral across 4 relevant articles.
0 positive · 4 neutral · 0 negativePatient CapitalQuiet
Activity-pressure buy-signal evidence highlights potential institutional accumulation windows.
No recent buy signal
06 · Catalysts and risk
What can move the shares—and how volatile the path has been
Event timing, options-implied movement, drawdown, and weekly return distribution frame the risk around the current setup.
Next earnings-No event is currently stored.
Options expected move-Nearest-chain priced movement where available.
52-week drawdown-12.2%Distance below the 52-week high.
13-week volatility3.9%Standard deviation of weekly returns.
Weekly gains and losses
Latest 26 completed weeksEach bar is one week. Gains rise above the zero line; losses fall below it. Taller bars mean a larger weekly move.
13 Feb
13 Mar
10 Apr
8 May
5 Jun
3 Jul
7 Aug
Weeks higher11 of 2613 weeks finished lower.
Best week+10.2%Week of 20 Feb.
Worst week-6.3%Week of 19 Jun.
Latest week+3.2%Week of 7 Aug.
Shape of recent returns
Strong gains3
Modest gains8
Flat weeks2
Modest losses11
Sharp losses2
Recent vol3.9%13-week weekly-return volatility.
Base vol4.8%52-week weekly-return volatility.
Up/down split18/27Count of positive and negative weeks in the 52-week window.
Average skew4.9% / -3.2%Average positive week versus average negative week.
07 · Sector and peer context
Is this stock leading—or simply moving with its group?
Sector and industry breadth distinguish company-specific strength from a broad group move.
SectorDE Healthcare
4-week rank17 / 78
Group average1.4%
Trend breadth39.7%
Trend39.7%active weekly trend signals
MD69.2%positive activity pressure
RS34.6%positive relative leadership
Four-week leaders
IndustryDE Drug Manufacturers - Specialty & Generic
4-week rank1 / 10
Group average-3.6%
Trend breadth30.0%
Trend30.0%active weekly trend signals
MD40.0%positive activity pressure
RS30.0%positive relative leadership
Four-week leaders
08 · Evidence and weekly data
The underlying research record
Every top-level statement above should be traceable to a stored market, fundamental, event, or positioning observation.
Weekly tape35/100
Trend, activity pressure, participation, and risk combine to a 35/100 tape read.
Indicator analysis14/100Latest 12-week confirmation: trend 0/12, activity pressure 1/12, relative leadership 0/12.
Activity pressure 0.20; No reversal markers Next-Week ExpectancyNegative 38.55%Next-week expectancy is negative with a 38.55% historical one-week setup read.
Adds short-term historical context without overriding trend, activity, or relative leadership. Factors56/100O'Shaughnessy factor stack blends value, quality, momentum, and confidence.
Buyback Yield rank 47 Patient CapitalQuietActivity-pressure buy-signal evidence highlights potential institutional accumulation windows.
No recent buy signal Sentiment50/100Weighted news tone is neutral across 4 relevant articles.
Biofrontera Plans Move from Prime Standard to Frankfurt’s Scale Segment Insiders50/100No recent insider transaction evidence is stored.
Earnings50/100No stored earnings event is currently attached to this ticker.
| Week | Close | Return | Trend Line | Fair Value | Pressure | Leadership | Volume | Trend |
|---|---|---|---|---|---|---|---|---|
| 7 Aug 2026 | 2.60 EUR | 3.2% | 2.51 EUR | 4.27 EUR | 0.28 | -6.51 | 1.4K | Off |
| 31 Jul 2026 | 2.52 EUR | -1.6% | 2.50 EUR | 4.35 EUR | -0.09 | -7.17 | 2.2K | Off |
| 24 Jul 2026 | 2.56 EUR | 8.0% | 2.51 EUR | 4.44 EUR | -0.52 | -4.08 | 11.3K | Off |
| 17 Jul 2026 | 2.37 EUR | -1.7% | 2.50 EUR | 4.53 EUR | -1.08 | -10.24 | 1.7K | Off |
| 10 Jul 2026 | 2.41 EUR | 2.6% | 2.50 EUR | 4.63 EUR | -1.09 | -9.70 | 1.4K | Off |
| 3 Jul 2026 | 2.35 EUR | 0.9% | 2.51 EUR | 4.73 EUR | -1.00 | -14.49 | 392 | Off |
| 26 Jun 2026 | 2.33 EUR | -2.5% | 2.52 EUR | 4.82 EUR | -0.80 | -11.53 | 100 | Off |
| 19 Jun 2026 | 2.39 EUR | -6.3% | 2.54 EUR | 4.92 EUR | -0.77 | -10.40 | 11 | Off |
| 12 Jun 2026 | 2.55 EUR | -1.5% | 2.55 EUR | 5.03 EUR | -0.66 | -3.15 | 0 | Off |
| 5 Jun 2026 | 2.59 EUR | 7.0% | 2.55 EUR | 5.13 EUR | -0.75 | -2.12 | 0 | Off |
| 29 May 2026 | 2.42 EUR | 0.0% | 2.56 EUR | 5.23 EUR | -0.71 | -9.79 | 3.1K | Off |
| 22 May 2026 | 2.42 EUR | 2.5% | 2.57 EUR | 5.34 EUR | -0.35 | -8.99 | 9.0K | Off |
| 15 May 2026 | 2.36 EUR | -3.3% | 2.57 EUR | 5.47 EUR | -0.17 | -8.01 | 7.2K | Off |
| 8 May 2026 | 2.44 EUR | -5.1% | 2.59 EUR | 5.60 EUR | 0.02 | -6.60 | 8.9K | Off |
How to use this report
This is a completed-week research summary. It explains the available evidence and its conflicts; it does not predict a guaranteed outcome or replace your own risk assessment. Fundamental figures may refer to an earlier financial reporting period, which is shown above.